Prevention and care targeting older adults are moving from being peripheral tasks in health policy to becoming core infrastructure. The development of GC Green Cross’s [GC3114B], the approval of the [APEC Healthy Aging Action Plan 2026–2030], and the operation of community-level [long-term care home medical centers] all stem from the judgment that in a super-aged society, health risks are difficult to manage with the existing one-size-fits-all services alone.
The meaning of this change lies in redesigning the healthcare system away from a model of bearing treatment costs after disease occurs and toward prevention and home-visit management tailored to age and mobility. Going forward, vaccines, long-term care, and digital-based management are increasingly likely to be integrated into a health system customized for older adults rather than functioning separately.
Postpartum herbal medicine is entering a stage of building evidence beyond experiential use. In a study tracking [186 postpartum women], the rate of adverse reactions was reported at around [0.6%], and Suwon City expanded discount support to first births as well as miscarriages and stillbirths, lowering the barrier to use. This shows that safety information is becoming intertwined with policy expansion.
At the same time, reflecting the reality that herbal and conventional medicines are often used together, an AI model called [Meta-HDI] has also emerged to predict interaction risks. This means that the key to expanding the use of Korean medicine is shifting away from simple accessibility and toward a precise safety management system that can explain who can safely use which medications together.
The government and the market are both moving to narrow the loose gaps in systems related to Korean medicine. In auto insurance, an [8-week] review standard has been introduced for the long-term treatment of patients with minor injuries. The Ministry of Health and Welfare, through the [detailed notice on fields prohibited from establishing new private certifications], has blocked the use of names similar to pharmacist, herbal pharmacist, and pharmacy, while the Ministry of Food and Drug Safety has made approval review standards more specific through revisions to the [Regulations on Product Approval and Notification for Herbal (Crude Drug) Preparations, etc.].
Behind this lies a shared problem: consumer confusion, leakage in insurance finances, and ambiguous market practices can no longer be left unaddressed. The simultaneous appearance of deregulated and tightened areas indicates a clearer direction—grow the industry, but manage cost claims and qualification labeling more strictly.
The axis of competition in the Korean medicine and natural products sector is no longer confined to the clinical setting; it is expanding to overseas certification, raw material self-sufficiency, and exhibition/export networks. The European [CPNP] registration of Jinan County’s red ginseng mask pack, the securing of propagation technology aimed at reducing a structure in which Asarum raw materials were [imported entirely from China], and the expansion to [50 participating companies] at the Jecheon expo all show that the industry is moving beyond the stage of domestic promotion into one of actual distribution and supply-chain competition.
This trend has emerged because the Korean medicine industry can no longer grow simply by making efficacy claims; it has now become a market in which the stability of raw materials, international standards, and sales channel security must all be demonstrated together. In the end, research and development and regional promotion projects are also increasingly likely to be reorganized away from event-centered efforts and toward proving export potential and supply stability.